BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/9/2022 12:48:14 PM | Browse: 650 | Download: 1745
 |
Received |
|
2022-04-29 06:55 |
|
Peer-Review Started |
|
2022-04-29 06:57 |
|
First Decision by Editorial Office Director |
|
2022-07-06 22:49 |
|
Return for Revision |
|
2022-07-06 22:49 |
|
Revised |
|
2022-07-20 05:38 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-08-09 02:55 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-08-10 04:24 |
|
Articles in Press |
|
2022-08-10 04:24 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-08-26 01:39 |
|
Publish the Manuscript Online |
|
2022-09-09 12:48 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xue-Qing Sheng, Hong-Zhi Wang, Shuai Li, Yang-Zi Zhang, Jian-Hao Geng, Xiang-Gao Zhu, Ji-Zhong Quan, Yong-Heng Li, Yong Cai and Wei-Hu Wang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Beijing Municipal Science and Technology Commission |
Z181100001718192 |
| Capital’s Funds for Health Improvement and Research |
2020-2-1027 |
| Capital’s Funds for Health Improvement and Research |
2020-1-4021 |
| National Natural Science Foundation |
82073333 |
|
| Corresponding Author |
Wei-Hu Wang, MD, Chief Physician, Department of Radiation Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Fucheng Road, Beijing 100142, China. wangweihu88@163.com |
| Key Words |
High-risk locally advanced rectal cancer; Neoadjuvant chemoradiotherapy; Capecitabine; Consolidation chemotherapy; Complete response |
| Core Tip |
This is the first study to explore the effects of one to two cycles of consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy (NCRT) in magnetic resonance imaging-defined high-risk patients with locally advanced rectal cancer without extending NCRT and surgery interval. After propensity score-matching and inverse probability of treatment weighting, the complete response rate increased. Although it showed no significant difference in long-term results, this relatively low-toxicity program deserves further exploration. |
| Publish Date |
2022-09-09 12:48 |
| Citation |
Sheng XQ, Wang HZ, Li S, Zhang YZ, Geng JH, Zhu XG, Quan JZ, Li YH, Cai Y, Wang WH. Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study. World J Gastrointest Oncol 2022; 14(9): 1711-1726 |
| URL |
https://www.wjgnet.com/1948-5204/full/v14/i9/1711.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v14.i9.1711 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
